

Specimen Instructions

FoundationOne®CDx is a broad companion diagnostic (CDx) test for multiple tumor types, including one pan-tumor indication. In addition to use as a companion diagnostic, FoundationOne CDx provides cancer relevant alterations that may inform patient management in accordance with professional guidelines. Information generated by this test is an aid in the identification of patients who are most likely to benefit from associated therapeutic products as noted in Table 1 of the Intended Use.¹




Acceptable Samples

- Formalin-fixed paraffin embedded (FFPE) specimens, including cut slide specimens are acceptable.
- Use standard fixation methods to preserve nucleic acid integrity. 10% neutral-buffered formalin for 6–72 hours is industry standard. DO NOT use other fixatives (Bouins, B5, AZF, Holland's).
- Do not decalcify.


SAMPLE SIZE

- 1** When feasible, please send the block + 1 H&E slide.*

10 unstained slides (positively charged and unbaked at 4-5 microns thick) + 1 H&E slide.*



OR




* For smaller samples, providing the original H&E will preserve material for testing.

SURFACE AREA

- 2** **MINIMUM: 25 mm²**

If sending slides, provide 10 unstained slides cut at 4-5 microns thick to achieve a tissue volume of 1 mm³.**



** Specimens with a smaller surface area may meet volume requirements by submitting additional unstained slides (USS) or block.

TUMOR CONTENT

- 3** **OPTIMUM: 30% TN** **MINIMUM: 20% TN**

Percent tumor nuclei (%TN) = number of tumor cells divided by total number of all cells with nuclei

Note for liver specimens: higher tumor content may be required because hepatocyte nuclei have twice the DNA content of other somatic nuclei

Shipping Instructions

1. Place the completed Foundation Medicine Test, Foundation Medicine Test Requisition Form, insurance information, and any other attachments into the FoundationOne CDx Specimen Shipping Kit.
2. Place the specimen shipping kit (including samples and paperwork) into the provided FedEx shipping pack, first ensuring that primary specimen containers (e.g. blocks, slides) are labeled with two patient-specific identifiers. Seal the shipping pack.
3. If using shipping pack provided in this kit (recommended), recording the Kit ID # will allow you to properly track specimen. If you use a different shipping pack, consider recording that pack's tracking #.
4. Call 800.463.3339 to request a pick-up or drop the package at your site's designated FedEx pick-up location and ship sealed shipping pack to:

Foundation Medicine, Inc.
150 Second Street
Cambridge, MA 02141
Phone: 888.988.3639

Intended Use and Limitations

FoundationOne®CDx (FICDX) is a next generation sequencing based *in vitro* diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed paraffin embedded (FFPE) tumor tissue specimens. The test is intended as a companion diagnostic to identify patients who may benefit from treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling. Additionally, FICDX is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. The FICDX assay is a single-site assay performed at Foundation Medicine, Inc. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For the complete label, including companion diagnostic indications and important risk information, please visit www.FICDXLabel.com

Table 1: Companion diagnostic indications

INDICATIONS	BIOMARKER	FDA-APPROVED THERAPY*
Non-Small Cell Lung Cancer (NSCLC)	<i>EGFR</i> exon 19 deletions and <i>EGFR</i> exon 21 L858R alterations	Gilotrif® (afatinib), Iressa® (gefitinib), Tagrisso® (osimertinib) or Tarceva® (erlotinib)
	<i>EGFR</i> exon 20 T790M alterations	Tagrisso® (osimertinib)
	<i>ALK</i> rearrangements	Alecensa® (alectinib), Xalkori® (crizotinib), or Zykadia® (ceritinib)
	<i>BRAF</i> V600E	Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib)
	<i>MET</i> single nucleotide variants (SNVs) and indels that lead to <i>MET</i> exon 14 skipping	Tabrecta™ (capmatinib)
Melanoma	<i>BRAF</i> V600E	Tafinlar® (dabrafenib) or Zelboraf® (vemurafenib)
	<i>BRAF</i> V600E or V600K	Mekinist® (trametinib) or Cotellic® (cobimetinib), in combination with Zelboraf® (vemurafenib)
Breast Cancer	<i>ERBB2</i> (HER2) amplification	Herceptin® (trastuzumab), Kadcyla® (ado-trastuzumab-emtansine), or Perjeta® (pertuzumab)
	<i>PIK3CA</i> alterations	Piqray® (alpelisib)
Colorectal Cancer	<i>KRAS</i> wild-type (absence of mutations in codons 12 and 13)	Erbix® (cetuximab)
	<i>KRAS</i> wild-type (absence of mutations in exons 2, 3 and 4) and <i>NRAS</i> wild-type (absence of mutations in exons 2, 3 and 4)	Vectibix® (panitumumab)
Ovarian Cancer	<i>BRCA1/2</i> alterations	Lynparza® (olaparib) or Rubraca® (rucaparib)
Cholangiocarcinoma	<i>FGFR2</i> fusions and select rearrangements	Pemazyre™ (pemigatinib)
Prostate Cancer	Homologous Recombination Repair (<i>HRR</i>) gene (<i>BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L</i>) alterations	Lynparza® (olaparib)
Solid tumors	TMB ≥ 10 mutations per megabase	Keytruda® (pembrolizumab)

Reference

1. For full information on the intended use, assay descriptions, and for detailed performance specifications, refer to the complete FoundationOne CDx label at www.foundationmedicine.com/f1cdx.

* Tarceva® is the registered trademark of OSI Pharmaceuticals, LLC. Zelboraf®, Herceptin®, Perjeta®, Kadcyla®, and Cotellic® are registered trademarks of Genentech, Inc. Gilotrif® is a registered trademark of Boehringer Ingelheim International GmbH. Iressa®, Lynparza®, and Tagrisso® are registered trademarks of the AstraZeneca group of companies. Xalkori® is a registered trademark of Pfizer Inc. Zykadia®, Tafinlar®, Piqray®, Mekinist®, and Tabrecta™ are registered trademarks of Novartis AG Corporation Switzerland. Erbitux® is a registered trademark of ImClone LLC, a wholly owned subsidiary of Eli Lilly and Company. Alecensa® is a registered trademark of Chugai Seiyaku Kabushiki Kaisha. Vectibix® is a registered trademark of Immunex Corporation. Rubraca® is a registered trademark of Clovis Oncology, Inc., Pemazyre™ is a registered trademark of Incyte Corporation, Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.